These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2179599)

  • 1. [Application of DDAVP for hemostatic control in platelet dysfunctions].
    Hattori A
    Rinsho Ketsueki; 1990 Jan; 31(1):1-9. PubMed ID: 2179599
    [No Abstract]   [Full Text] [Related]  

  • 2. Desmopressin in inherited disorders of platelet function.
    Coppola A; Di Minno G
    Haemophilia; 2008 Jan; 14 Suppl 1():31-9. PubMed ID: 18173692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmopressin in the treatment of patients with defects of platelet function.
    Cattaneo M
    Haematologica; 2002 Nov; 87(11):1122-4. PubMed ID: 12414337
    [No Abstract]   [Full Text] [Related]  

  • 4. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS; Faiz A; Miller CH; Saidi P; Philipp CS
    Haemophilia; 2008 May; 14(3):571-8. PubMed ID: 18312366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of DDAVP in patients with functional thrombocyte disorders].
    Schäfer G; Wahl G; Budde U
    Dtsch Zahnarztl Z; 1984 Sep; 39(9):718-21. PubMed ID: 6386440
    [No Abstract]   [Full Text] [Related]  

  • 6. PFA-100 test in the detection of platelet dysfunction and monitoring DDAVP in a patient with liver cirrhosis undergoing inguinal hernia repair.
    Vucelić D; Golubović M; Bjelović M
    Srp Arh Celok Lek; 2012; 140(11-12):782-5. PubMed ID: 23350257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-deamino-8-D-arginine vasopressin (DDAVP) normalized the bleeding time in patients with platelet disorder characterized by defective calcium ionophore-induced platelet aggregation.
    Fuse I; Higuchi W; Aizawa Y
    Br J Haematol; 2003 Sep; 122(5):870-1. PubMed ID: 12930404
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of desmopressin in open-heart surgery.
    Cattaneo M
    Haemophilia; 2008 Jan; 14 Suppl 1():40-7. PubMed ID: 18173693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome.
    Pfueller SL; Howard MA; White JG; Menon C; Berry EW
    Thromb Haemost; 1987 Dec; 58(4):1060-3. PubMed ID: 3502198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Desmopressin for the treatment of aspirin-induced platelet dysfunction.
    Schulz-Stübner S
    Neurocrit Care; 2011 Feb; 14(1):148. PubMed ID: 20717749
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanisms of platelet dysfunction and response to DDAVP in patients with congenital platelet function defects. A double-blind placebo-controlled trial.
    Rao AK; Ghosh S; Sun L; Yang X; Disa J; Pickens P; Polansky M
    Thromb Haemost; 1995 Oct; 74(4):1071-8. PubMed ID: 8560416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP normalized the bleeding time in patients with congenital platelet TxA2 receptor abnormality.
    Fuse I; Higuchi W; Mito M; Aizawa Y
    Transfusion; 2003 May; 43(5):563-7. PubMed ID: 12702175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time.
    Cattaneo M; Pareti FI; Zighetti M; Lecchi A; Lombardi R; Mannucci PM
    J Lab Clin Med; 1995 Apr; 125(4):540-7. PubMed ID: 7706911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Force monitoring of clot retraction during DDAVP therapy for the qualitative platelet disorder of uraemia: report of a case.
    Carr ME; Zekert SL
    Blood Coagul Fibrinolysis; 1991 Apr; 2(2):303-8. PubMed ID: 1893061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Desmopressin as a hemostatic. Selective treatment is most effective].
    Flordal A; Schött U
    Lakartidningen; 1994 Jan; 91(4):236-8. PubMed ID: 8309329
    [No Abstract]   [Full Text] [Related]  

  • 16. Desmopressin (dDAVP): a powerful general hemostatic agent?
    Drouet L; Scrobohaci ML; Boudaoud S; Vilain G
    Nouv Rev Fr Hematol (1978); 1989; 31(2):163-5. PubMed ID: 2528120
    [No Abstract]   [Full Text] [Related]  

  • 17. [Hemostatic control in platelet dysfunction and abnormality by DDAVP].
    Mito M; Higuchi W; Fuse I; Hattori A; Shibata A
    Nihon Rinsho; 1992 Feb; 50(2):355-9. PubMed ID: 1613990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Physiopathology and therapy of platelet function disorders].
    Watanabe K
    Nihon Naika Gakkai Zasshi; 1991 Jun; 80(6):860-5. PubMed ID: 1919200
    [No Abstract]   [Full Text] [Related]  

  • 19. PFA-100 testing for pretherapeutic assessment of response to DDAVP in patients with von Willebrand's disease.
    Weston H; Just S; Williams B; Rowell J; Kennedy GA
    Haemophilia; 2009 Jan; 15(1):372-3. PubMed ID: 19149861
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation.
    Casonato A; Steffan A; Pontara E; Zucchetto A; Rossi C; De Marco L; Girolami A
    Thromb Haemost; 1999 Feb; 81(2):224-8. PubMed ID: 10063996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.